This book presents state of the art knowledge on the psychopathology, clinical symptomatology, biology, and treatment of hallucinations in patients with psychoses and affective disorders. The opening section describes and examines the origins of the hallucinatory symptoms associated with schizophrenia, bipolar disorders, and drug- or substance-induced psychoses. In addition, progress in understanding of hallucinations in children and adolescents and chronic hallucinatory disorder is reviewed, and the value of a Research Domain Criteria approach in elucidating the emergence of auditory hallucinations is explained. The biological basis of hallucinations is then closely scrutinized with reference to recent genetic research, neurochemical studies, and functional and structural neuroimaging data. Outcomes of a meta-analysis of diffusion tensor imaging studies regarding the association between white matter integrity and auditory verbal hallucinations are highlighted. The closing chapters focus on the roles of drug treatment and electric and magnetic brain stimulation techniques. The book will be of wide interest to psychiatrists and clinical psychologists.

lgli/O:\genesis4\!!!springer\10.1007%2F978-3-319-75124-5.pdf

lgrsnf/O:\genesis4\!!!springer\10.1007%2F978-3-319-75124-5.pdf

nexusstc/Hallucinations in Psychoses and Affective Disorders: A Clinical and Biological Approach/fc04ed05d13fd896fc6dd6f2407d3134.pdf

scihub/10.1007/978-3-319-75124-5.pdf

zlib/Psychology/Clinical Psychology/Paolo Brambilla, Massimo Carlo Mauri, Alfredo Carlo Altamura/Hallucinations in Psychoses and Affective Disorders: A Clinical and Biological Approach_3661019.pdf

Brambilla, Paolo; Mauri, Massimo Carlo; Altamura, Alfredo Carlo

Springer Nature Switzerland AG

Springer Nature, Cham, 2018

Switzerland, Switzerland

Cham, Swtizerland, 2018

1st ed. 2018, US, 2018

Sep 27, 2018

sm71931096

producers:
Adobe PDF Library 10.0.1

{"edition":"1","isbns":["3319751239","3319751247","9783319751238","9783319751245"],"publisher":"Springer"}

Source title: Hallucinations in Psychoses and Affective Disorders: A Clinical and Biological Approach

Presentation 5
Contents 8
Contributors 10
Part I: Neurotransmission and Psychopathology 13
1: Substances of Abuse and Hallucinogenic Activity: The Dopaminergic Pathway - Focus on Cocaine and Amphetamine-type Stimulants 14
1.1 Focus on Cocaine 14
1.1.1 Molecular Mechanism 15
1.1.2 Conclusions 18
1.2 Focus on Amphetamine-Type Stimulants 18
1.2.1 Molecular Mechanism 19
1.2.2 Conclusions 21
References 22
2: Substances of Abuse and Hallucinogenic Activity: The Serotoninergic Pathway - Focus on Classical Hallucinogens and Entactogens 28
2.1 Focus on Classical Hallucinogens 28
2.1.1 Molecular Mechanism 29
2.1.2 Conclusions 32
2.2 Focus on Entactogens 32
2.2.1 Molecular Mechanism 33
2.2.2 Conclusions 35
References 36
3: Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway - Focus on Ketamine 43
3.1 Focus on Ketamine 43
3.1.1 Molecular Mechanism 44
References 48
4: Chronic Hallucinatory Disorder “an Equivalent” of Delusional Disorder 52
4.1 Introduction 52
4.2 Hallucinatory Disorder: Clinical Picture 54
4.3 Hallucinatory Disorder: Neurocognitive Aspects 56
4.4 Hallucinatory Disorder: Neuroimaging Data 57
References 63
5: Hallucinations in the Substance-Induced Psychosis 66
5.1 Introduction 66
5.1.1 Symptoms 67
5.1.2 Epidemiology 68
5.1.3 Differential Diagnosis 68
5.2 Substance-Induced Psychosis Versus Primary Psychosis 69
5.2.1 Treatments 72
5.2.2 Prognosis 73
5.2.3 Prevention 73
5.3 Stimulant Drug-Induced Psychosis 73
5.3.1 Amphetaminic Substances 75
5.3.1.1 Therapy 78
5.3.2 MDMA (Ecstasy) 78
5.3.2.1 Therapy 79
5.3.3 Cocaine 80
5.3.3.1 Therapy 81
5.4 Hallucinogenic Drug-Induced Psychosis 82
5.4.1 Phencyclidine and Ketamine 83
5.4.2 LSD 84
5.4.3 Therapy 85
5.5 Cannabis-Induced Psychosis 86
5.5.1 Therapy 87
5.6 Alcohol-Induced Psychosis 87
5.6.1 Therapy 89
Bibliography 89
6: Hallucinatory Symptomatology in Major Psychoses (Schizophrenia and Bipolar Disorders) 93
6.1 Introduction 93
6.2 Hallucinations in Bipolar Disorder Versus Schizophrenia: A Concise Look at the Status of Comparative Empirical Research 95
6.3 A Phenomenological Reappraisal of BD and Schizophrenia 97
6.4 The Psychotic Syndrome as a Trajectory 101
References 101
7: Hallucinations in Neurological Disorders 106
7.1 Hypnic Hallucinations (HH) 106
7.2 Peduncular Hallucinosis (PH) 108
7.3 Charles Bonnet Syndrome (CBS) 109
7.4 Migraine 111
7.5 Epilepsy 113
7.6 Intellectual Disability 114
7.7 Neurodegenerative Disorders 115
7.7.1 Alzheimer’s Disease (AD) 115
7.7.2 Parkinson’s Disease (PD) 116
7.7.3 Dementia with Lewy Bodies (DLB) 117
7.7.4 Frontotemporal Dementia (FTD) 121
7.8 Prion Diseases 121
7.9 Hallucinations Associated with Other Medical Conditions 122
7.9.1 Delirium 122
7.9.2 Paraneoplastic Neurological Syndromes 123
7.9.3 Systemic Lupus Erythematosus (SLE) 124
7.9.4 Hashimoto’s Encephalopathy 125
7.9.5 Behçet’s Syndrome 125
7.9.6 Neurosyphilis 126
7.9.7 Inborn Errors of Metabolism 126
References 127
Part II: Genetics and Neuroimaging 138
8: Genetic Basis of Auditory Verbal Hallucinations in Schizophrenia 139
8.1 Introduction 139
8.2 Language-Specific Gene and Auditory Hallucination in Schizophrenia 140
8.3 Hallucinations and Aberrant Source Monitoring: Genetic Basis 141
8.3.1 Hallucinations in 22q11.2 Deletion Syndrome 142
8.3.2 Hallucinations and DTNBP1 Gene 143
8.4 Genetic Expressions of Dopaminergic Activity: Aberrant Salience and Genesis of Hallucinations 144
8.5 Emotional Valence, Genes, and Hallucinations 146
8.6 Summary 148
References 148
9: Imaging Genetics of Hallucinations 154
9.1 Introduction 154
9.2 Variations in the Gene ZNF804a and Severity of Hallucinations in Schizophrenia 155
9.3 Imaging Genetics Results of FOX Gene: The Impact on Psychopathology 156
9.4 The Effect of DISC1 Variations on Brain Structure and the Severity of Hallucinations 157
9.5 Indirect Findings Linking Genes, Brain, and Hallucinations in Psychosis 158
9.5.1 miR-137 and MIR137HG 158
9.5.2 COMT and PRODH 159
9.5.3 Polygenic Risk Score 160
9.6 Final Remarks 160
References 160
10: Dysconnectivity in Hallucinations 163
10.1 Introduction 163
10.2 Auditory Verbal Hallucinations 164
10.2.1 In First-Episode Psychosis and Schizophrenia 164
10.2.2 Mood Disorders 168
10.3 Visual Hallucinations 168
10.3.1 In First-Episode Psychosis and Schizophrenia 168
10.3.2 In Parkinson’s Disease 169
10.3.3 When Exposed to Psychedelic Drugs 169
10.4 Summary and Conclusions 170
References 171
Part III: Treatment 176
11: Translating Neurocognitive Models of Auditory Verbal Hallucinations in Schizophrenia into Novel Therapeutic Interventions 177
11.1 Introduction 177
11.2 Self-Monitoring, Predictive Coding, and the Auditory Cortex 178
11.3 Reality Monitoring Deficits and AVH 181
11.4 Connectivity and AVH 183
11.5 Can Neurocognitive Models of AVH Inform New Interventions? 185
11.6 Conclusions and Future Directions 187
References 187
12: Innovative Approaches to Hallucinations in Psychosis and Affective Disorders: A Focus on Noninvasive Brain Stimulation Interventions 193
12.1 Transcranial Magnetic Stimulation (TMS) 197
12.2 Transcranial Direct Current Stimulation (tDCS) 202
12.3 Limitations and Future Perspectives 205
References 206

Front Matter ....Pages i-xiii
Front Matter ....Pages 1-1
Substances of Abuse and Hallucinogenic Activity: The Dopaminergic Pathway - Focus on Cocaine and Amphetamine-type Stimulants (Matteo Lazzaretti, Gian Mario Mandolini, Alfredo Carlo Altamura, Paolo Brambilla)....Pages 3-16
Substances of Abuse and Hallucinogenic Activity: The Serotoninergic Pathway - Focus on Classical Hallucinogens and Entactogens (Matteo Lazzaretti, Gian Mario Mandolini, Alfredo Carlo Altamura, Paolo Brambilla)....Pages 17-31
Substances of Abuse and Hallucinogenic Activity: The Glutamatergic Pathway - Focus on Ketamine (Gian Mario Mandolini, Matteo Lazzaretti, Alfredo Carlo Altamura, Paolo Brambilla)....Pages 33-41
Chronic Hallucinatory Disorder “an Equivalent” of Delusional Disorder (Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Chiara Rovera, Giorgio Marotta, Alfredo Carlo Altamura)....Pages 43-56
Hallucinations in the Substance-Induced Psychosis (Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace)....Pages 57-83
Hallucinatory Symptomatology in Major Psychoses (Schizophrenia and Bipolar Disorders) (Andrea Raballo, Michele Poletti, Mads Gram Henriksen)....Pages 85-97
Hallucinations in Neurological Disorders (Alessio Di Fonzo, Edoardo Monfrini, Paola Basilico, Andrea Arighi)....Pages 99-130
Front Matter ....Pages 131-131
Genetic Basis of Auditory Verbal Hallucinations in Schizophrenia (Anushree Bose, Venkataram Shivakumar, Ganesan Venkatasubramanian)....Pages 133-147
Imaging Genetics of Hallucinations (Jacqueline Mayoral-van Son, Julio Sanjuan, Benedicto Crespo-Facorro)....Pages 149-157
Dysconnectivity in Hallucinations (Branislava Ćurčić-Blake, Josselin Houenou, Renaud Jardri)....Pages 159-171
Front Matter ....Pages 173-173
Translating Neurocognitive Models of Auditory Verbal Hallucinations in Schizophrenia into Novel Therapeutic Interventions (Natasza Orlov, Jane Garisson, Paul Allen)....Pages 175-190
Innovative Approaches to Hallucinations in Psychosis and Affective Disorders: A Focus on Noninvasive Brain Stimulation Interventions (Bernardo Dell’Osso, M. Carlotta Palazzo, Alfredo Carlo Altamura)....Pages 191-208

2018-09-14